Rejected at 4:26 p.m. Dec, 29, 2025 ] by Ahmed7
Author: henryzou
Related Note: 1481330867563 2
Rationale for change

Treatment for polycythemia vera:

First-line: {{c1::phlebotomy}}
Second-line: {{c1::hydroxyurea}}
Third-line: {{c1::ruxolitinib}}
Source: Society Guidelines - https://www.nejm.org/doi/full/10.1056/NEJMoa1409002

Extra Extra
Text
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Empty field
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Empty field
Physeo
Empty field
Bootcamp
OME
Additional Resources
One by one
Empty field
#AK_Step1_v12::#OME::Clinical::04_Organ_Systems::05_Hematology_Oncology::04_Proliferation::02_Myeloproliferation #AK_Step2_v12::#Resources_by_rotation::FM::ome::neuro::stroke #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::04_Pathology::29_Myeloproliferative_neoplasms #AK_Step1_v12::#SketchyPharm::08_Antineoplastics::01_Antimetabolites::01_Methotrexate,_leucovorin,_5-fluorouracil,_hydroxyurea #AK_Step2_v12::!Shelf::IM::no_dupes #AK_Step2_v12::Original_decks::Dorian::neuro::ome::stroke #AK_Step2_v12::#AMBOSS #AK_Step2_v12::#Subjects::Hematology::02_RBC::04_Procedures::Phlebotomy #AK_Other::Only_Step_1&2_Overlap #AK_Step1_v12::#SketchyPath::10_Myeloid_&_Lymphoid::01_Myeloid_Disorders::01_Myeloproliferative_Neoplasms_&_Myelodysplastic_Syndromes #AK_Step2_v12::#OME::02_Neurology::01_Stroke #AK_Step2_v12::#AMBOSS::zt0rT3 #AK_Step1_v12::#Pathoma::06_WBC::04_Myeloproliferative #AK_Step2_v12::#AMBOSS::ZF0Zg3 #AK_Step2_v12::#Subjects::Hematology::03_WBC::04_Myeloproliferative_Disorders::Polycythemia_Vera #AK_Step1_v12::#Physeo::11_Pathology::10_HemeOnc_Pathology::14_Myeloproliferative_Disorders #AK_Step1_v12::#NinjaNerd::09_Hematology::02_Pathology::13_Myeloproliferative_Neoplasias_(MPN) #AK_Step2_v12::#Resources_by_rotation::IM::uw::heme/onc::heme/onc_zanki #PANCE::HEME::cytoses #AK_Step2_v12::#OME::01_Medicine::05_Hematology_Oncology::05_Leukemia #AK_Step2_v12::#B&B::07_Hematology_and_Oncology::03_White_Cells::02_Myeloproliferative_Disorders #AK_Other::#AK_Original_Decks::Step_2::Cheesy_Dorian_(M3) #AK_Step2_v12::#Resources_by_rotation::IM::uw::heme/onc::heme/onc_dorian #AK_Step2_v12::#Resources_by_rotation::IM::ome::heme/onc::leukemia #AK_Step2_v12::Original_decks::Dorian::fam::ome::neuro::stroke #AK_Step2_v12::Original_decks::Zanki_Step_2::IM::HemeOnc #AK_Step2_v12::#Resources_by_rotation::Neuro::ome::stroke #AK_Step2_v12::Original_decks::Dorian::im::ome::heme/onc::leukemia #AK_Step1_v12::#NinjaNerd::09_Hematology::02_Pathology::17_Hypercoagulable_States #AK_Step1_v12::#Bootcamp::Genetics::01_DNA_Structure::05_Clinical_Applications_of_the_Pyrimidine_Pathway #AK_Step1_v12::#OME::04_Organ_Systems::05_Hematology_Oncology::04_Proliferation::02_Myeloproliferation #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::10_Plasma_Cell_Dyscrasias_&_Myeloproliferative_Disease::03_Polycythemia_Vera_&_Essential_Thrombocythemia #AK_Step2_v12::#UWorld::Step::2883 #AK_Step2_v12::Original_decks::Dorian::im::uw::heme/onc #AK_Other::#AK_Original_Decks::Step_1::Zanki_Step_Decks::Zanki_Hematology_&_Oncology::Pathoma_WBC #AK_Step1_v12::#SketchyPath::10_Myeloid_&_Lymphoid::01_Myeloid_Disorders::03_Polycythemia #AK_Step1_v12::^Systems::HemeOnc::WBC #AK_Step1_v12::#AMBOSS::qiaCs4 #AK_Step2_v12::#SketchyIM::08_Hematology_&_Oncology::03_Myeloproliferative_Disorders::02_Polycythemia_Vera #AK_Step2_v12::#UWorld::COMLEX::28693 #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::04_Pathology::29_Myeloproliferative_neoplasms::01_Polycythemia_vera #AK_Step2_v12::#SketchyIM::08_Hematology_&_Oncology::03_Myeloproliferative_Disorders::01_Myeloproliferative_Disorders_Overview #AK_Step2_v12::#AMBOSS::-t0DT3 #AK_Other::^EXPN::BGedit #AK_Step1_v12::#Low/HighYield::1-HighYield #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::04_Pathology::31_Polycythemia::*Polycythemia_Vera